Quick Answer
Seres Therapeutics, Inc. reported Cash And Cash Equivalents At Carrying Value of $45.77 million for the year ending 2025.
- Seres Therapeutics, Inc. showed an increase of +48.6% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Seres Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 14 years of available data (2012 to 2025), Seres Therapeutics, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 636.4%.
- Historical annual values: Fiscal year 2025: $45.77 million | Fiscal year 2024: $30.79 million | Fiscal year 2023: $127.97 million | Fiscal year 2022: $163.03 million | Fiscal year 2021: $180.00 million | Fiscal year 2020: $116.05 million | Fiscal year 2019: $65.13 million | Fiscal year 2018: $85.82 million | Fiscal year 2017: $36.09 million | Fiscal year 2016: $54.54 million | Fiscal year 2015: $73.93 million | Fiscal year 2014: $114.19 million | Fiscal year 2013: $1.65 million | Fiscal year 2012: $6.22 million.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: